Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes

Anticancer Research

Volumn 17, Issue 2 A, 1997, Pages 1083-1088

  Nagy, Eva ^a   Baral, Edward ^b   Kangas, Lauri ^c   Berczi, Istvan ^a,d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Manitoba Cancer Treatment and Research Foundation   (Canada)

^c ORION CORPORATION   (Finland)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cytotoxic T lymphocytes; Estrogen receptor; Immunotherapy; Mouse; P815 mastocytoma; Tamoxifen; Target cell sensitization; Toremifene

Indexed keywords

ANTIESTROGEN; CHROMIUM 51; CIS TAMOXIFEN CITRATE; INTERLEUKIN 2; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMIUM 51 RELEASE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; HOST RESISTANCE; IMMUNOLOGICAL MEMORY; IMMUNOTHERAPY; MASTOCYTOMA; MORTALITY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SPLEEN; TUMOR GROWTH;

EID: 0030896072     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Klein G, Sjögren HO, Klein E and Hellstrom KE: Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 20: 1561-1572, 1960.
2. Berczi I, Strausbauch P and Sehon AH: Rejection of tumor cells in vitro. Science 180: 1289-1291, 1973.
3. Berczi I and Sehon AH: Effector and suppressor lymphoid cells in tumor bearing guinea pigs. Int J Cancer 23: 274-282, 1979.
4. Mule JJ, Hellstrom I and Hellstrom KE: Cell surface phenotypes of radiolabeled immune long-lived lymphocytes that selectively localize in syngeneic tumours. Am J Pathol 107: 142-149, 1982.
5. Austin FC, Finerty JF and Sogn JA: Cancer immunology: highlights of the NCI extramural immunology program. Cancer Invest 8: 207-228, 1990.
6. Hellstrom I and Hellstrom KE: Tumor immunology: an overview. Ann NY Acad Sci 690: 24-33, 1993.
7. Berczi I, Nagy E and Baral E: The amplification of cell-mediated cytolysis by estradiol and tamoxifen. 8th Int Congress of Immunology, August 23-28, 1992, Budapest, Hungary.
8. Baral E, Nagy E and Berczi I: Tamoxifen as an immunomodulatory agent. In: Advances in Psychoneuroimmunology (Berczi I and, Szelenyi J, eds) Plenum press, 1994b, pp. 233-241.
9. Kallio S. Kangas L, Blanco G. Johannson R, Karjalainen A, Perila M, Pippo I, Sundquist H, Soderwall M. Toivola R: A new triphenylethylene compound, Fc1157a. I. Hormonal effects, Cancer Chemother Pharmacol 17: 103-108, 1986.
10. Kangas L, Nieminen A-L, Blanco G, Gronroos M, Kallio S, Karjalainen A, Perila M, Sodervall M, Toivola R: A new triphenylethylene compound. Fc-1157a. II. Antitumor effects. Cancer Chemother Pharmacol 17: 109-113, 1986
11. Baral E, Nagy E and Berczi I: Enhancement of natural killer cell mediated cytotoxicity by tamoxifen. Cancer 75: 591-599, 1995.
12. Baral E, Nagy E and Berczi I: Target cells are sensitized for cytotoxic T-lymphocyte-mediated destruction by estradiol and tamoxifen. Int J Cancer 58: 64-68, 1994.
13. Laatikainen A: Immune response against P815×2 mastocytoma growing in syngeneic DBA/2 mice. Scand J Immunol 30: 479-455, 1989.
14. Berczi I: Cancer immunology - Quo vadis? An overview, J Exp Clin Cancer Res 2: 135-144, 1983.
15. Wang KC, Berczi I, Hoffman EG and Schon AH: Effector and enhancing lymphoid cells in plasmacytoma bearing mice. II. Dynamic changes during tumor progression. Int J Cancer 25: 493-501, 1980.
16. Teodorczyk-Injeyan J, Cembrzynska-Nowak M, Lalani S and Kellen JA: Modulation of biological responses of normal human mononuclear cells by antiestrogens. Anticancer Res 13: 279-283, 1993.
17. Nagy E and Berczi I: Immunomodulation by tamoxifen and pergolide. Immunopharmacology 12:145-153, 1986.
18. Baral E, Nagy E and Berczi I: The effect of tamoxifen on the immune response. In: Tamoxifen: Beyond the Antiestrogen (Kellen JA, ed). Boston, MA, Birkhauser, 1996, pp. 137-178.
19. Paavonen T, Anderson LC: The oestrogen antagonists, tamoxifcn and FC-1157a, display oestrogen like effects on human lymphocyte functions in vitro. Clin exp Immunol 61: 467-474, 1985.
20. Valavaara R, Tuominen J, Toivanen A: The immunological status of breasat cancer patients during treatment with a new antiestrogen, toremifene. Cancer Immunol Immunother. 31: 381-386, 1990.
21. Paavonen T, Aronen H, Pyrhonen S, Hajba A, Andersson A: The effects of antiestrogen therapy on lymphocyte functions in breast cancer patients. APMIS 99: 163-170, 1991.
22. Berczi I: Studies in tumor immunology. Ph.D. thesis. The University of Manitoba, 1972.